Straits Times Index
3,332.80 -10.55 (-0.32%) Nikkei
39,583.08 +241.54 (+0.61%) Hang Seng
17,718.61 +2.14 (+0.01%) FTSE 100
8,227.72 +48.04 (+0.59%) Bitcoin USD
61,468.13 +368.79 (+0.60%) CMC Crypto 200
1,281.87 -1.96 (-0.15%)
NUCANA SP.ADR 25/ LS-,04 (N04.BE)
| Previous close | 2.5600 |
| Open | 2.5600 |
| Bid | 2.4200 x N/A |
| Ask | 2.7200 x N/A |
| Day's range | 2.5600 - 2.5600 |
| 52-week range | 2.5600 - 24.0000 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 14 Aug 2024 - 19 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
NuCana to Present at the Jefferies Global Healthcare Conference
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Global Healthcare Conference. Event: Jefferies Global Healthcare ConferenceDate: Thursday, June 6, 2024Time: 12:30 PM EDTLocation: New York, NY The presentation will be webcast live and available for replay under “Events & Presentations” in the Investors section of the C
- GlobeNewswire
NuCana to Present at TD Cowen’s 5th Annual Oncology Innovation Summit
EDINBURGH, United Kingdom, May 21, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present at TD Cowen’s 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA. Event: TD Cowen’s 5th Annual Oncology Innovation SummitDate: Tuesday, May 28, 2024Time: 8:30 AM EDTLocation: Virtual The presentation will be webcast live and available for replay under “Events & Presentations” in the Inve
- GlobeNewswire
NuCana Reports First Quarter 2024 Financial Results and Provides Business Update
Key Data Readouts on Track for All Programs in 2024 Randomized Phase 2 Study of 182 Second-Line Colorectal Cancer Patients Fully Enrolled NUC-7738 plus Pembrolizumab Demonstrated Encouraging Anti-Cancer Activity in Several Patients who were Resistant to PD-1 Inhibitors Anticipated Cash Runway into Q1 2025 EDINBURGH, United Kingdom, May 16, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the first quarter ended March 31, 2024 and provided an update on its broad
